|Bid||65.04 x 100|
|Ask||65.64 x 400|
|Day's Range||64.56 - 65.60|
|52 Week Range||55.10 - 66.80|
|PE Ratio (TTM)||41.72|
|Dividend & Yield||1.88 (2.91%)|
|1y Target Est||N/A|
U.S. stocks traded mostly lower on Wednesday as oil prices failed to rebound from a sharp fall during the previous session.
Given the company’s industry leading position, solid fundamentals and attractive stock valuation, we view it as a preferable alternative to traditional competitors in its industry.
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.